Home Tags Antibody-drug Conjugates

Tag: Antibody-drug Conjugates

The ceramic dragon fountain in the Parc Guell designed by Antoni Gaudi, Barcelona, Spain.

ESMO 2019: Seattle Genetics to Present Latest Study Data – Becomes...

Peter Hofland, Ph.D -
Seattle Genetics. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Biologics License Application and Priority Review for Enfortumab Vedotin in Urothelial...

Peter Hofland, Ph.D -

Investigational ADC is Well Tolerated with Partial Dose-dependent Response in NSCLC

Peter Hofland, Ph.D -
Featured Image: Daiichi Sankyo Booth at the annual meeting of the American Association for Cancer Research (AACR) 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

WCLC 2019: Daiichi Sankyo to Present Results from First-in-class HER3...

Peter Hofland, Ph.D -
Doctor discussing treatment options with a patient.

Belantamab Mafodotin Shows Positive Results in Multiple Myeloma Study

Peter Hofland, Ph.D -
Seattle Genetics. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Astellas Pharma and Seattle Genetics Confirm BLA Submission for Enfortumab Vedotin

Peter Hofland, Ph.D -
General views of the 55th Annual Meeting of the American Association of Clinical Oncology (ASCO) - held in the McCormick Place in Chicago, Ill. Courtesy: 2019 ? ASCO/Luke Franke 2019.

RC48-ADC Shows Clinically Meaningful Results in Advanced HER2+ Urothelial Cancer

Peter Hofland, Ph.D -
Exhibition booth Seattle Genetics - ASCO 2019 | Courtsey: Emila Duaerte / Sunvalley Communication

Enfortumab Vedotin Produces a High Tumor Response Rate in Patients with...

Peter Hofland, Ph.D -
Annual Meeting of the American Society of Clinical Oncology

Sanofi’s Oncology Targets Highlighted at Annual ASCO Meeting

Peter Hofland, Ph.D -

Daiichi Sankyo Accelerates Biologics License Application for Trastuzumab Deruxtecan

Peter Hofland, Ph.D -
123Page 1 of 3

LATEST

© 2019 Sunvalley Communication, LLC. All Rights Reserved.